Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.51 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | GNPAT | O15228 | 2/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099613 | 0.92 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGNPATSLC15A2 | |
| SCHEMBL30565198 | 0.92 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGNPATSLC15A2 | |
| SCHEMBL31479983 | 0.91 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGNPATNMT2 | |
| SCHEMBL29893500 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGNPATSLC15A2 | |
| SCHEMBL709721 | 0.88 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL29725450 | 0.88 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL935610 | 0.88 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL31522798 | 0.88 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGNPATNMT2 | |
| SCHEMBL30496531 | 0.88 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGNPATNMT2 | |
| SCHEMBL30381819 | 0.88 | FOLH1 (0.56) | FOLH1NAALAD2NMT2NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541817-A2 | NUCLEIC ACID MOLECULE ENCODING CAR AND VECTOR INCLUDING THE SAME, IMMUNE CELL COMPRISING CAR AND PHARMACEUTICAL COMPOSITION INCLUDING THE CELL, METHOD FOR IMPROVING CYTOTOXIC ACTIVITY, AND METHOD FOR PRODUCING IMMUNE CELL COMPRISING CAR | Mie University (JP) | 2025-04-23 | — | — | EP | disclosed |
| CN-119613563-A | Nucleic acid molecule encoding CAR, carrier containing CAR, immune cell containing CAR, manufacturing method of immune cell, pharmaceutical composition containing CAR and method for improving cell injury activity | 国立大学法人三重大学 | 2025-03-14 | — | — | CN | disclosed |
| US-20250084180-A1 | NUCLEIC ACID MOLECULE ENCODING CAR AND VECTOR COMPRISING THE SAME, IMMUNE CELL INCLUDING CAR AND PHARMACEUTICAL COMPOSITION COMPRISING THE CELL, METHOD FOR IMPROVING CYTOTOXIC ACTIVITY, AND METHOD FOR PRODUCING IMMUNE CELL INCLUDING CAR | MIE UNIVERSITY (JP) | 2025-03-13 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230167478-A1 | IDENTIFYING AND CLASSIFYING MICROORGANISMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-06-01 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4143872-A1 | IDENTIFYING AND CLASSIFYING MICROORGANISMS | Board of Regents, The University of Texas System (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220305079-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220306691-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4058465-A1 | CXCR4 ANTAGONIST PEPTIDES | Cohbar Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220226484-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4013440-A1 | THERAPEUTIC PEPTIDES | Cohbar Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022087224-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | MMP1, MMP8, COL2A1 | FOLH1 391/4885NAALAD2 1774/4885RIMKLA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.